insights_auto
Why is TWST down 4.07%?
Dive Deeperchevron_right
TWST:NASDAQ
Twist Bioscience Corp
$111.62
arrow_downward
-4.07%(-4.73) 1D
$107.00
arrow_downward
-4.14% (-4.62)todayPre-market
Closed: Nov 19, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TWST...
Open
$120.50
High
$125.16
Low
$110.39
Mkt. cap
7.61B
Avg. vol.
2.54M
Volume
5.39K
52-wk high
$219.71
52-wk low
$25.67
EPS
-$2.08
Beta
2.25
Shares outstanding
68.18M
No. of employees
1K
Open
$120.50
High
$125.16
Low
$110.39
Mkt. cap
7.61B
Avg. vol.
2.54M
Volume
5.39K
52-wk high
$219.71
52-wk low
$25.67
EPS
-$2.08
Beta
2.25
Shares outstanding
68.18M
No. of employees
1K
News stories
From web sources and news partners
Investing.com Canada
·
18 hours ago
Form 144 Twist Bioscience Corp For: 19 November By Investing.com
Investing.com
·
1 day ago
Cathie Wood’s ARK sells BYD stock, buys Kodiak AI and Twist Bioscience
Profile
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
About Twist Bioscience Corp
CEOEmily LeProust
Employees1.08K
Founded2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitetwistbioscience.com
Analyst ratings
Based on 9 analysts giving stock ratings to TWST in the past 3 months
Buy
Buy
6
Hold
2
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for TWST in the last 3 months.
Highest
Current $111.62
$175.00 (+56.78%)
Average
$132.44 (+18.65%)
Lowest
$45.00 (-59.68%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Puneet Souda Leerink Partners | Buy | Reiterated | $175.00 | +56.8% | 11/16/2026 |
Brendan Smith TD Cowen | Buy | Reiterated | $137.00 | +22.7% | 11/13/2026 |
Catherine Ramsey Schulte Robert W. Baird | Buy | Maintained | $135.00 | +20.9% | 11/13/2026 |
Subbu Nambi Guggenheim | Buy | Reiterated | $150.00 | +34.4% | 11/12/2026 |
Luke Sergott Barclays | Buy | Maintained | $130.00 | +16.5% | 11/13/2026 |
Doug Schenkel UBS | Hold | Maintained | $120.00 | +7.5% | 11/13/2026 |
Kyle Mikson CFA Canaccord Genuity | Buy | Reiterated | $150.00 | +34.4% | 11/13/2026 |
Matthew Stanton, CFA Jefferies | Hold | Initiated | $150.00 | +34.4% | 10/07/2026 |
Hamed Khorsand BWS Financial | Sell | Maintained | $45.00 | -59.7% | 09/18/2026 |
Unknown Analyst UBS | Hold | Initiated | $144.00 | +29% | 09/08/2026 |
David Westenberg Piper Sandler | Buy | Reiterated | $115.00 | +3% | 08/05/2026 |
Matt Larew William Blair | Buy | Reiterated | - | - | 08/03/2026 |
Vijay Kumar Evercore ISI | Hold | Downgraded | $102.00 | -8.6% | 07/06/2026 |
Last report
Nov 12, 2026
Fiscal period
Q4 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.02 / -$0.20
+89.90%beat
arrow_upward
Revenue / Est. (USD)
126.64M / 123.58M
+2.48%beat
arrow_upward
Fiscal Q4 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 103.70M | 110.72M | 118.38M | 126.64M |
Cost of goods sold | 49.73M | 53.59M | 55.92M | 59.39M |
Cost of revenue | 49.73M | 53.59M | 55.92M | 59.39M |
Research and development expenses | 17.13M | 19.70M | 18.02M | 16.99M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 69.74M | 76.08M | 80.71M | 74.68M |
Operating expense | 86.87M | 95.78M | 98.73M | 91.66M |
Total operating expenses | 136.60M | 149.37M | 154.66M | 151.06M |
Operating income | -32.90M | -38.66M | -36.28M | -24.41M |
Other non operating income | 471.00K | 175.00K | 40.00K | 170.00K |
EBT including unusual items | -30.25M | -43.98M | -34.74M | -20.82M |
EBT excluding unusual items | -30.25M | -36.77M | -34.74M | -20.82M |
Income tax expense | 253.00K | 43.00K | 311.00K | -201.00K |
Effective tax rate | -0.84% | -0.10% | -0.90% | 0.97% |
Other operating expenses | - | - | - | - |
Net income | -30.51M | -44.02M | -35.05M | -20.62M |
Net profit margin | -29.42% | -39.76% | -29.61% | -16.28% |
Earnings per share | -0.50 | -0.60 | -0.56 | -0.02 |
Interest and investment income | 2.18M | 1.71M | 1.50M | 3.42M |
Interest expense | - | - | - | - |
Net interest expenses | 2.18M | 1.71M | 1.50M | 3.42M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -27.01M | -32.44M | -29.80M | -17.93M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events